These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9182920)

  • 21. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis.
    Hui W; Bell M; Carroll G
    Ann Rheum Dis; 1997 Mar; 56(3):184-7. PubMed ID: 9135222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The levels of leukemia inhibitory factor in synovial tissues of patients with rheumatoid arthritis: inflammation and other proinflammatory cytokines.
    Enomoto H; Saito S; Yabe H; Toyama Y; Tomatu T
    Mod Rheumatol; 2003 Jun; 13(2):121-8. PubMed ID: 24387170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo.
    Langdon C; Kerr C; Hassen M; Hara T; Arsenault AL; Richards CD
    Am J Pathol; 2000 Oct; 157(4):1187-96. PubMed ID: 11021823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): regulation of its production and possible roles in bone metabolism.
    Ishimi Y; Abe E; Jin CH; Miyaura C; Hong MH; Oshida M; Kurosawa H; Yamaguchi Y; Tomida M; Hozumi M
    J Cell Physiol; 1992 Jul; 152(1):71-8. PubMed ID: 1618924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.
    Fearon U; Mullan R; Markham T; Connolly M; Sullivan S; Poole AR; FitzGerald O; Bresnihan B; Veale DJ
    Arthritis Rheum; 2006 Oct; 54(10):3152-62. PubMed ID: 17009243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture.
    Isozaki O; Tsushima T; Miyakawa M; Emoto N; Demura H; Arai M; Sato-Nozoe Y
    Thyroid; 1997 Feb; 7(1):71-7. PubMed ID: 9086575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients.
    Chung SJ; Kwon YJ; Park MC; Park YB; Lee SK
    Yonsei Med J; 2011 Jan; 52(1):113-20. PubMed ID: 21155043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.
    Liu FL; Chen CH; Chu SJ; Chen JH; Lai JH; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2007 Aug; 46(8):1266-73. PubMed ID: 17569750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncostatin M is a differentiation factor for myeloid leukemia cells.
    Bruce AG; Hoggatt IH; Rose TM
    J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration.
    Tanida S; Yoshitomi H; Ishikawa M; Kasahara T; Murata K; Shibuya H; Ito H; Nakamura T
    Cytokine; 2011 Aug; 55(2):237-44. PubMed ID: 21592822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.
    Roşu A; Mărgăritescu C; Stepan A; Muşetescu A; Ene M
    Rom J Morphol Embryol; 2012; 53(1):73-80. PubMed ID: 22395503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
    Robak E; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 1997 Sep; 8(3):281-6. PubMed ID: 9346362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
    Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
    Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating levels of IL-11 and leukaemia inhibitory factor (LIF) do not significantly participate in the production of acute-phase proteins by the liver.
    Gabay C; Singwe M; Genin B; Meyer O; Mentha G; LeCoultre C; Vischer T; Guerne PA
    Clin Exp Immunol; 1996 Aug; 105(2):260-5. PubMed ID: 8706331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
    Barksby HE; Milner JM; Patterson AM; Peake NJ; Hui W; Robson T; Lakey R; Middleton J; Cawston TE; Richards CD; Rowan AD
    Arthritis Rheum; 2006 Oct; 54(10):3244-53. PubMed ID: 17009259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of chemokines by leukemia inhibitory factor, interleukin-6 and oncostatin M.
    Hartner A; Goppelt-Struebe M; Hocke GM; Sterzel RB
    Kidney Int; 1997 Jun; 51(6):1754-60. PubMed ID: 9186863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.
    Nishimoto N; Ogata A; Shima Y; Tani Y; Ogawa H; Nakagawa M; Sugiyama H; Yoshizaki K; Kishimoto T
    J Exp Med; 1994 Apr; 179(4):1343-7. PubMed ID: 8145046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts.
    Mun SH; Kim JW; Nah SS; Ko NY; Lee JH; Kim JD; Kim DK; Kim HS; Choi JD; Kim SH; Lee CK; Park SH; Kim BK; Kim HS; Kim YM; Choi WS
    Arthritis Rheum; 2009 Mar; 60(3):678-85. PubMed ID: 19248119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.